Upstream Bio (UPB) EBIT: 2023-2024

Historic EBIT for Upstream Bio (UPB) over the last 2 years, with Dec 2024 value amounting to -$77.8 million.

  • Upstream Bio's EBIT fell 100.25% to -$37.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$140.5 million, marking a year-over-year decrease of 113.62%. This contributed to the annual value of -$77.8 million for FY2024, which is 93.86% down from last year.
  • Per Upstream Bio's latest filing, its EBIT stood at -$77.8 million for FY2024, which was down 93.86% from -$40.1 million recorded in FY2023.
  • Upstream Bio's 5-year EBIT high stood at -$40.1 million for FY2023, and its period low was -$77.8 million during FY2024.
  • In the last 2 years, Upstream Bio's EBIT had a median value of -$58.9 million in 2023 and averaged -$58.9 million.
  • Data for Upstream Bio's EBIT shows a maximum YoY plummeted of 93.86% (in 2024) over the last 5 years.
  • Upstream Bio's EBIT (Yearly) stood at -$40.1 million in 2023, then tumbled by 93.86% to -$77.8 million in 2024.